Ordermade treatment using analysis of EGFR gene abnormality in non-small cell lung cancer

1.我们使用13种不同突变的探针，包括11种已经报道的突变，使用TaqMan PCR检测方法对2000-2006年间在名古屋市立大学医院手术的400例非小细胞肺癌患者的EGFR突变状态进行了基因分型。我们评估了EGFR突变、临床病理因素、吉非替尼敏感性、我们在之前的论文中表明TaqMan PCR检测方法足够灵敏，可以检测到9倍过量野生型样本污染的样本中的突变，因此，我们分析了从CT引导活检或经支气管活检获得的小样本.一些研究报道，下游信号分子、EGFR基因扩增和其他ErbB受体的表达是吉非替尼敏感性的其他预测因素。因此，我们对EGFR拷贝数、ErbB 2拷贝数和PIK 3CA基因突变等其他生物标志物进行了分析，并评价了它们与临床病理因素的关系.我们在年度会议上报告了这些研究，并将其作为一篇文章发表。在未来，我们希望使用TaqMan PCR检测EGFR突变状态有助于定制治疗

1. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 400 non small cell lung cancer patients operated between 2000-2006 at Nagoya CityUniversity Hospital using the TaqMan PCR assay.We have evaluated the relationships among the EGFR mutation, clinical-pathologic factors, gefitinib sensitivity, and overall survival.We show in our previous paper that the TaqMan PCR assay is sensitive enough to detect the mutation in samples contaminated with 9 fold excess of wild type samples.Therefore, we have analyzed small samples obtained from CT guided biopsy or trans-bronchial biopsy.2. Some studies reported that downstream signaling molecules, EGFR gene amplification, and the expression of the other ErbB receptors were the other predictors of gefitinib sensitivity. Therefore, we have analyzed the other biomarkers, as the EGFR copy number, the ErbB2 copy number and PIK3CA gene mutation and have evaluated the relationship between their biomarkers and clinical-pathologic factors.3. We have reported these studies at the annual meetings and have published them as an article.4. In the future, we hope that EGFR mutation status using TaqMan PCR assay contributes to made-to-order treatment